Clinical Features and Risk Factors for Mortality Among Long-term Care Facility Residents Hospitalized Due to COVID-19 in Spain.


Journal

The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837

Informations de publication

Date de publication:
01 04 2022
Historique:
received: 12 07 2021
pubmed: 10 10 2021
medline: 6 4 2022
entrez: 9 10 2021
Statut: ppublish

Résumé

COVID-19 severely impacted older adults and long-term care facility (LTCF) residents. Our primary aim was to describe differences in clinical and epidemiological variables, in-hospital management, and outcomes between LTCF residents and community-dwelling older adults hospitalized with COVID-19. The secondary aim was to identify risk factors for mortality due to COVID-19 in hospitalized LTCF residents. This is a cross-sectional analysis within a retrospective cohort of hospitalized patients ≥75 years with confirmed COVID-19 admitted to 160 Spanish hospitals. Differences between groups and factors associated with mortality among LTCF residents were assessed through comparisons and logistic regression analysis. Of 6 189 patients ≥75 years, 1 185 (19.1%) were LTCF residents and 4 548 (73.5%) were community-dwelling. LTCF residents were older (median: 87.4 vs 82.1 years), mostly female (61.6% vs 43.2%), had more severe functional dependence (47.0% vs 7.8%), more comorbidities (Charlson Comorbidity Index: 6 vs 5), had dementia more often (59.1% vs 14.4%), and had shorter duration of symptoms (median: 3 vs 6 days) than community-dwelling patients (all, p < .001). Mortality risk factors in LTCF residents were severe functional dependence (adjusted odds ratios [aOR]: 1.79; 95% confidence interval [CI]: 1.13-2.83; p = .012), dyspnea (1.66; 1.16-2.39; p = .004), SatO2 < 94% (1.73; 1.27-2.37; p = .001), temperature ≥ 37.8°C (1.62; 1.11-2.38; p = .013); qSOFA index ≥ 2 (1.62; 1.11-2.38; p = .013), bilateral infiltrates (1.98; 1.24-2.98; p < .001), and high C-reactive protein (1.005; 1.003-1.007; p < .001). In-hospital mortality was initially higher among LTCF residents (43.3% vs 39.7%), but lower after adjusting for sex, age, functional dependence, and comorbidities (aOR: 0.74, 95%CI: 0.62-0.87; p < .001). Basal functional status and COVID-19 severity are risk factors of mortality in LTCF residents. The lower adjusted mortality rate in LTCF residents may be explained by earlier identification, treatment, and hospitalization for COVID-19.

Sections du résumé

BACKGROUND
COVID-19 severely impacted older adults and long-term care facility (LTCF) residents. Our primary aim was to describe differences in clinical and epidemiological variables, in-hospital management, and outcomes between LTCF residents and community-dwelling older adults hospitalized with COVID-19. The secondary aim was to identify risk factors for mortality due to COVID-19 in hospitalized LTCF residents.
METHODS
This is a cross-sectional analysis within a retrospective cohort of hospitalized patients ≥75 years with confirmed COVID-19 admitted to 160 Spanish hospitals. Differences between groups and factors associated with mortality among LTCF residents were assessed through comparisons and logistic regression analysis.
RESULTS
Of 6 189 patients ≥75 years, 1 185 (19.1%) were LTCF residents and 4 548 (73.5%) were community-dwelling. LTCF residents were older (median: 87.4 vs 82.1 years), mostly female (61.6% vs 43.2%), had more severe functional dependence (47.0% vs 7.8%), more comorbidities (Charlson Comorbidity Index: 6 vs 5), had dementia more often (59.1% vs 14.4%), and had shorter duration of symptoms (median: 3 vs 6 days) than community-dwelling patients (all, p < .001). Mortality risk factors in LTCF residents were severe functional dependence (adjusted odds ratios [aOR]: 1.79; 95% confidence interval [CI]: 1.13-2.83; p = .012), dyspnea (1.66; 1.16-2.39; p = .004), SatO2 < 94% (1.73; 1.27-2.37; p = .001), temperature ≥ 37.8°C (1.62; 1.11-2.38; p = .013); qSOFA index ≥ 2 (1.62; 1.11-2.38; p = .013), bilateral infiltrates (1.98; 1.24-2.98; p < .001), and high C-reactive protein (1.005; 1.003-1.007; p < .001). In-hospital mortality was initially higher among LTCF residents (43.3% vs 39.7%), but lower after adjusting for sex, age, functional dependence, and comorbidities (aOR: 0.74, 95%CI: 0.62-0.87; p < .001).
CONCLUSION
Basal functional status and COVID-19 severity are risk factors of mortality in LTCF residents. The lower adjusted mortality rate in LTCF residents may be explained by earlier identification, treatment, and hospitalization for COVID-19.

Identifiants

pubmed: 34626477
pii: 6385886
doi: 10.1093/gerona/glab305
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e138-e147

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

José-Manuel Ramos-Rincón (JM)

Clinical Medicine Department, Miguel Hernandez University of Elche, Alicante, Spain.

Máximo Bernabeu-Wittel (M)

Internal Medicine Department, Virgen del Rocío University Hospital, Seville, Spain.
Medicine Department, University of Seville, Sevilla, Spain.

Isabel Fiteni-Mera (I)

Internal Medicine Department, Royo Villanova Hospital, Zaragoza, Spain.

Almudena López-Sampalo (A)

Internal Medicine Department, Málaga Regional University Hospital- Biomedical Research Institute of Málaga (IBIMA), Málaga, Spain.

Carmen López-Ríos (C)

Internal Medicine Department, Virgen del Rocío University Hospital, Seville, Spain.

María-Del-Mar García-Andreu (MD)

Internal Medicine Department, Royo Villanova Hospital, Zaragoza, Spain.

Juan-José Mancebo-Sevilla (JJ)

Internal Medicine Department, Málaga Regional University Hospital- Biomedical Research Institute of Málaga (IBIMA), Málaga, Spain.

Carlos Jiménez-Juan (C)

Internal Medicine Department, Virgen del Rocío University Hospital, Seville, Spain.

Marta Matía-Sanz (M)

Internal Medicine Department, Royo Villanova Hospital, Zaragoza, Spain.

Pablo López-Quirantes (P)

Internal Medicine Department, Málaga Regional University Hospital- Biomedical Research Institute of Málaga (IBIMA), Málaga, Spain.

Manuel Rubio-Rivas (M)

Internal Medicine Department, Bellvitge University Hospital- -IDIBELL, L'Hospitalet de Llobregat (Barcelona), Spain.

Diana Paredes-Ruiz (D)

Internal Medicine Department, 12 Octubre University Hospital, Madrid, Spain.

Candela González-San-Narciso (C)

Internal Medicine Department, Gregorio Marañon University Hospital, Madrid, Spain.

Rocío González-Vega (R)

Internal Medicine Department, Costa del Sol Hospital, Marbella (Malaga), Spain.

Pablo Sanz-Espinosa (P)

Internal Medicine Department, Rio Hortega University Hospital, Valladolid, Spain.

Almudena Hernández-Milián (A)

Internal Medicine Department, Son Llàtzer University Hospital, Palma de Mallorca, Spain.

Amara Gonzalez-Noya (A)

Internal Medicine Department, Ourense University Hospital Complex, Ourense, Spain.

Ricardo Gil-Sánchez (R)

Internal Medicine Department, La Fe University Hospital, Valencia, Spain.

Ramon Boixeda (R)

Internal Medicine Department, Mataró Hospital, Mataró (Barcelona), Spain.

José-Nicolás Alcalá-Pedrajas (JN)

Internal Medicine Department, Pozoblanco Hospital, Pozoblanco (Cordoba), Spain.

Marta Palop-Cervera (M)

Internal Medicine Department, Sagunto University Hospital, Sagunto (Valencia), Spain.

Begoña Cortés-Rodríguez (B)

Internal Medicine Department, Alto Guadalquivir Hospital, Andújar (Jaén), Spain.

María-Esther Guisado-Espartero (ME)

Internal Medicine Department, Infanta Margarita Hospital, Cabra (Córdoba), Spain.

Carmen Mella-Pérez (C)

Internal Medicine Department, Ferrol University Hospital Complex, (Ferrol) A Coruna, Spain.

Ricardo Gómez-Huelgas (R)

Internal Medicine Department, Málaga Regional University Hospital- Biomedical Research Institute of Málaga (IBIMA), Málaga, Spain.
Medicine Department, University of Malaga, Malaga, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH